Definium Therapeutics, Inc. DFTX
32.70 USD -0.71 (-2.13%)
At closeNov 4, 2026, 4:01 PM EST
32.70 0.00 0.00%
After hours · Nov 4, 4:01 PM ET
31.71 Day range 33.87
10.68 52-week range 48.45
- YTD
- +144.21%
- 1 year
- +172.50%
- Market cap
- 4.39B
- EPS (ttm)
- -3.36
- Shares out
- 134.37M
- Forward P/E
- -16.85
- YTD return
- +144.21%
- 1-year return
- +172.50%
- Volume
- 1.41M
- Avg volume
- 2.18M
- Open
- 33.48
- Previous close
- 33.41
- Day's range
- 31.71 – 33.87
- 52-week range
- 10.68 – 48.45
- Beta
- 2.21
- Analysts
- Strong Buy
- Price target
- 72.56 (+121.9%)
- Earnings date
- Nov 9, 2026
2Y +26.55 (+431.71%)
Key statistics
- Enterprise value
- 3.44B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 7.61M
- Total cash
- 1.08B
- Total debt
- 36.47M
- Return on equity
- -64.09%
- Short % of float
- 7.52%
- 50-day average
- 37.32
- 200-day average
- 29.78
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 72.56 +121.9% upside
Now 32.70
- Target (low)
- 55.00
- Target (mean)
- 72.56
- Target (high)
- 91.00
Ratings (0m) 19 19 buy · 0 hold · 0 sell
- Strong buy5
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.56065.
Financials — quick view
DFTX Revenue — quarterly 0
DFTX Net income — quarterly -158.99M
DFTX EPS — quarterly -1.44
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.56294 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.54102 | -1.44 | -0.90 | -166.16% |
| May 7, 2026 | Mar 31, 2026 | -0.47 | -0.71 | -0.24 | -51.06% |
| Feb 26, 2026 | Dec 31, 2025 | -0.48368 | -0.51 | -0.03 | -5.44% |
| Nov 6, 2025 | Sep 30, 2025 | -0.52 | -0.78 | -0.26 | -50.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.38 | -0.50 | -0.12 | -31.58% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | JP Morgan | init | — | Overweight |
| Sep 15, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 15, 2026 | Baird | main | Outperform | Outperform |
| Sep 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 14, 2026 | Needham | reit | Buy | Buy |
| Sep 11, 2026 | RBC Capital | reit | Outperform | Outperform |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- definiumtx.com
News
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress 
Definium Therapeutics to Participate at Upcoming Investor Conferences 
Definium Therapeutics Announces New Employee Inducement Grants 
Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Average Target Price of $66.00 According to Analysts 
Definium Therapeutics Announces New Employee Inducement Grants 
JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84 
Definium Therapeutics Announces New Employee Inducement Grants 
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression 
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression 
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
Your note
Sign in to keep a note on DFTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Adsett (Roger) | Director of Issuer | Opening Balance-Initial SEDI Report | Jan 28, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.36% | 11,232,834 | 367.31M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.35% | 7,188,888 | 235.08M | Jun 29, 2026 |
| Driehaus Capital Management, LLC | 5.09% | 6,845,276 | 223.84M | Jun 29, 2026 |
| Jupiter Topco LLC | 4.18% | 5,615,645 | 183.63M | Jun 29, 2026 |
| Capital World Investors | 3.99% | 5,367,723 | 175.52M | Jun 29, 2026 |
| FMR, LLC | 3.54% | 4,752,921 | 155.42M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.63% | 10,253,153 | 335.28M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.41% | 3,243,233 | 106.05M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.11% | 1,486,832 | 48.62M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.06% | 1,424,929 | 46.60M | Aug 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.96% | 1,287,318 | 42.10M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.87% | 1,170,713 | 38.28M | Sep 29, 2026 |